Cardiff Oncology, Inc. announced on April 23, 2025, that the United States Patent and Trademark Office (USPTO) has issued U.S. patent No. 12,263,173. This new patent covers the method of using onvansertib in combination with bevacizumab (bev) for the treatment of metastatic colorectal cancer (mCRC) patients who have not previously been treated with bev, across any line of therapy. The patent is expected to expire no earlier than 2043.
This second patent significantly expands Cardiff Oncology's intellectual property portfolio, building upon a previous patent issued last fall that covered the use of onvansertib for first-line treatment of bev-naïve patients with a KRAS mutation. The newly issued patent encompasses all mCRC patients, including those with RAS-mutated or RAS wild-type mCRC, broadening the potential market for onvansertib.
The expanded patent protection strategically positions onvansertib for broader market opportunities and future growth. This extensive applicability has the potential to drive widespread adoption and facilitate seamless integration into clinical practice, potentially redefining the standard of care for mCRC. Onvansertib is currently being evaluated in the first-line Phase 2 CRDF-004 trial, with additional clinical data expected in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.